Key F3Q26 takeaways include: 1) we look for a number of powerful catalysts to increasingly drive accelerating revenue growth including ongoing initiatives to broaden product and distribution capabilities, thereby expanding ETST's TAM 2) management announced a series of initiatives designed to institutionalize the business, attract new investors, and drive long-term value creation including pending votes on the potential retirement of ETST's Series B Preferred Stock, as well as "say on pay" to better align management incentives with shareholder interests. and 3) key margin expansion drivers likely include an ongoing sales mix shift in favor of non-sterile compounding medications (carrying higher gross margins), compensation relief (assuming shareholder approval), and ETST's holding company structure that enables subsidiaries to leverage centralized corporate functions.
